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Abstract
Introduction: It is now well accepted that sepsis is associated with the development of a pronounced
immunosuppressive state, characterized by severe immune alterations (e.g. reduced proliferative capacity,
endotoxin tolerance, apoptosis) participating in increased mortality and susceptibility to nosocomial infections.
Efforts are currently aimed at restoring a functional immune response in septic patients. Successful therapy
depends on the identification of appropriate immunostimulatory drugs and on the development of suitable
biomarkers that could be used to stratify patients and to follow response to treatment.
Methods: In this study, we evaluated the ex vivo effect of recombinant interferon gamma (rIFN-g) in restoring
monocyte functionality (endotoxin-induced Tumor Necrosis Factor-a production) in a two-hit model of endotoxin
tolerance (ET) with peripheral blood mononuclear cells from healthy volunteers and in whole blood of septic shock
patients. Importantly, we used quantitative-reverse transcription polymerase-chain reaction to monitor the effect of
rIFN-g on the expression of seven genes known to participate in ET (TNF-a, IL-10, HLA-DRA, CIITA, IRAK-M, ABIN-3
and LY64).
Results: Expression analysis of those genes confirmed the presence of an immunosuppression state and the ex
vivo restoration of immune functions by rIFN-g. We show for the first time that rIFN-g is able to bypass, at the
mRNA level, the effect of negative regulators of the LPS signalling pathway such as IRAK-M, ABIN-3 and LY64.
Conclusions: Overall, mRNA expressions of a panel of genes could represent promising candidates for the ex vivo
evaluation of rIFN-g effect on monocyte functionality. This ex vivo translational research study demonstrates the
potential of a mRNA-based approach to successfully monitor drug efficacy.
Introduction
D e s p i t ea d v a n c e si ns u p p o r t i v ec a r ea n dan u m b e ro f
clinical trials, sepsis remains the leading cause of death
in non-coronary ICUs [1].
With a better understanding of the pathophysiology of
sepsis, it is now evident that the early pro-inflammatory
phase of the disease is immediately followed by an anti-
inflammatory response that rapidly results in an immu-
nosuppressive state. Immunosuppression is believed to
be responsible for the increased risk of nosocomial
infections and mortality [1-3] and represents an innova-
tive target for future clinical trials. Current challenges
consist of finding appropriate immunostimulant drugs,
identifying patients that would benefit from immunomo-
dulatory therapies (tailored immunotherapy) and moni-
toring successful response to treatment. As suggested by
Carlet et al. [4], the development of biological models
representative of the immunosuppressive state of the
disease and the use of biomarkers may facilitate testing
of immunostimulant drugs and the monitoring of
response to treatment.
Among other alterations, sepsis-induced immunosup-
pression is characterized by dramatic monocyte/macro-
phage dysfunctions [1-3,5]. The intensity of such
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of death and nosocomial infections in septic patients.
Interestingly, these alterations have been partly repro-
duced in an ex vivo model of endotoxin tolerance (ET).
Indeed, ex vivo prior exposure of innate immune cells to
minute amounts of endotoxin causes a temporary insen-
sitivity and renders cells refractory to subsequent lipo-
polysaccharide (LPS) challenge [6,7]. As observed in
patients, this phenomenon is associated with monocyte/
macrophage functional alterations, including a reduction
in the production of pro-inflammatory cytokines asso-
ciated with an increased expression of anti-inflammatory
cytokines [6-10] and a decrease in antigen presenting
capacity partly due to a reduced HLA-DR expression
[11-15]. Moreover, LPS unresponsiveness is associated
with the upregulation of numerous mechanisms that
negatively regulate toll-like receptor (TLR)-associated
signaling pathways [6,7].
In this study we evaluated in an ex vivo experimental
model of ET the potential of an immunostimulating
therapy (recombinant Interferon (IFN)-g)t h a th a sb e e n
proposed as a potential innovative treatment for sepsis
[11-13]. Importantly, and as a proof of concept, we
monitored response to treatment through the expression
level of genes that have been shown in the literature to
be involved in ET (TNF-a, IL-10, HLA-DRA, CIITA,
LY64, IRAK-M and ABIN-3). Using gene expression ana-
lysis we confirmed the inflammatory properties of rIFN-
g. More importantly, restoration of ET-induced mono-
cyte dysfunction by rIFN-g was found in clinical samples
from septic shock patients.
Materials and methods
Preparation of PBMCs and experimental settings of ET
model
A ss h o w ni nF i g u r e1 a ,h u m a np e r i p h e r a lb l o o dm o n o -
nuclear cells (PBMCs) from healthy volunteers were iso-
lated from citrated venous blood by Ficoll-Paque density
gradient centrifugation (Amersham Biosciences, Björkga-
tan, Sweden) and washed with PBS while the remaining
red blood cells were lysed. Cells were cultured in 24-well
plates at 2 × 10
6 cells/ml in X-Vivo 20 Medium (Lonza,
Verviers, Belgium). Blood from healthy volunteers was
obtained from EFS (Etablissement Francais du Sang). To
induce the LPS-primed state, PBMCs were cultured in
the presence or absence (control group) of 2 ng/ml LPS
mix from Escherichia coli O55:B5, O127:B8 and O111:B4
(Sigma-Aldrich, Deisenhofen, Germany) and incubated
overnight at 37°C and 5% CO2 (15 hours). Following a
washing step, PBMCs were incubated for an additional
24 hours in the presence or absence (control group sti-
mulated or not with LPS) of rIFN-g1b (Imukin, Boehrin-
ger, Ingelheim, Austria). Finally, cells were stimulated a
second time by adding 100 ng/ml of LPS for another six
hours. TNF-a and IL-10 protein concentrations in those
supernatants were assessed as well as mRNA expressions
in cell pellets. For each condition, supernatants and cell
pellets were recovered and stored at -80°C for TNF-a
and IL-10 measurements by ELISA and at -20°C for RNA
extractions and quantifications by quantitative-reverse
transcription polymerase chain reaction (qRT-PCR),
respectively.
Functional testing by ELISA
Detection of TNF-a and IL-10 concentrations in
PBMCs culture supernatants was done by using com-
mercially available ELISA kits from R&D System (Min-
neapolis, MN, USA).
RNA extraction and cDNA synthesis by reverse
transcription
T o t a lR N Aw a se x t r a c t e df r o mP B M C su s i n gR N e a s y
Plus Mini kits (Qiagen, Hilden, Germany) or from
whole blood using QIAamp RNA Blood Mini Kit (Qia-
gen, Hilden, Germany). For each RNA extraction, the
residual genomic DNA was digested using the gDNA
Eliminator spin column (Qiagen, Hilden, Germany).
RNA was diluted in 30 μl of elution buffer. RNA quan-
tity was determined for each sample using a Qubit (Invi-
trogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Then, cDNA was synthe-
sized from 100 ng of total RNA using SuperScript
®
VILO™ system (Invitrogen, Carlsbad, CA, USA) accord-
ing to manufacturer’s instructions.
Quantitative PCR analysis
mRNA expression level was quantified using qRT-PCR.
Briefly, PCR reactions were performed in a LightCycler
®
480 instrument using the associated SYBR Green I Mas-
ter Mix according to the manufacturer’si n s t r u c t i o n s
(Roche Molecular Biochemicals, Indianapolis, IN, USA).
For amplification, the reaction volume was 20 μl, and
the cycling conditions were as follows: an initial dena-
turation step at 95°C for five minutes (one cycle), fol-
lowed by 45 cycles of a touch-down PCR protocol (20
seconds at 95°C, 15 seconds annealing at 68 to 58°C and
15 seconds extension at 72°C), a melting curve at 95°C
for one second, 60°C for 10 seconds and 95°C for five
minutes, and to finish a cooling at 40°C for 30 seconds.
mRNA expression levels of the housekeeping gene Pep-
tidylpropyl isomerase B (PPIB), encoding for cyclophilin
B, and TNF-a were investigated using specific cDNA
standards and ready-to-use primer mixes obtained from
Search-LC (Search-LC, Heidelberg, Germany). The effi-
ciency of PPIB mRNA levels as reference for target
mRNA quantification has been previously demonstrated
in human peripheral blood [16]. The PCR amplicons of
the genes of interest (IL-10, HLA-DRA, CIITA, LY64,
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Page 2 of 11IRAK-M and ABIN-3) were obtained with the primer
combinations presented in Table 1. Serial dilutions of
the cDNA were prepared in quadruplicate to generate
standard curves. Relative standard curves, describing the
PCR efficiency of the genes panel and PPIB,w e r ec r e -
ated and used to perform efficiency-corrected quantifi-
cation with the LightCycler Software version 1.5. An
internal calibrator was used to compare each cDNA
amplification. The results are expressed as fold change
normalized ratio of TNF-a, IL-10, HLA-DRA, CIITA,
LY64, IRAK-M and ABIN-3 mRNA relative to PPIB
mRNA. qRT-PCR results were included in the analysis
only when PPIB and target mRNA values were com-
prised within the standard curve.
Septic shock patients and whole blood model
The study group consisted of eight consecutive septic
shock patients according to the diagnostic criteria of the
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Figure 1 TNF-a and IL-10 protein and mRNA expressions in the ex vivo model of endotoxin tolerance. (a) Schematic representation of
the endotoxin tolerance (ET) model used in the present study. (b) TNF-a and IL-10 protein concentrations and (c) mRNA expressions were
assessed, respectively, by ELISA in culture supernatant or by quantitative RT-PCR in cell pellet obtained in peripheral blood mononuclear cells
(PBMCs) after ET induction. Mean (± standard deviation) data from 10 independent experiments in healthy volunteers are given. Gene expression
results are presented as a normalized ratio vs data obtained in unstimulated cells (fold changes vs control). Black columns represent controls
(cells without any lipopolysaccharide (LPS) stimulation), white columns indicate LPS-unprimed cells (only stimulated once with 100 ng/ml LPS)
and grey columns show LPS-primed cells (two LPS stimulations: 2 ng/ml followed by 100 ng/ml). The Wilcoxon signed rank test was used to
test for statistical significance (** P < 0.005 vs LPS-unprimed cells). IFN, interferon.
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Care Medicine [17]. Patients were admitted to the two
participating ICUs (one medical, one surgical) of the
Lyon-Sud University Hospital (Hospices Civils de Lyon,
France). Septic shock was defined by an identifiable site of
infection, evidence of a systemic inflammatory response
manifested by at least two of the following criteria: a) tem-
perature more than 38°C or less than 36°C; b) heart rate
above 90 beats per minute; c) respiratory rate above 20
breaths per minute; d) white blood cell count above
12,000 cells/mm
3 or less than 4,000 cells/mm
3 and hypo-
tension persisting despite fluid resuscitation and requiring
vasopressor therapy. The onset of septic shock was defined
by the beginning of vasopressive therapy. The only exclu-
sion criteria were patients younger than 18 years old and
the absence of circulating leukocytes. Patients were treated
according to the standardized recommendations of our
ICUs. Severity at the onset of shock was assessed by the
Simplified Acute Physiology Score II (SAPS II, range: 0 to
194) [18]. Development of organ dysfunctions was
assessed by the Sequential Organ Failure Assessment
score (SOFA, range: 0 to 24) measured after 24 hours of
ICU stay [19].
EDTA whole blood was collected from eight patients
within three days after the onset of shock and from
eight healthy volunteers. After centrifugation and
removal of plasma, 3 ml of blood was diluted 1:1 with 3
ml of RPMI 1640 medium (Eurobio, Courtaboeuf,
France) and then cultured in presence or absence (con-
trol group) of 100 ng/ml LPS +/- 100 ng/ml rIFN-g1b
(Imukin, Boehringer, Ingelheim, Austria) overnight at
37°C and 5% CO2 (15 hours). For each condition, super-
natants and cell pellets were recovered and stored at
-80°C for TNF-a measurement by ELISA and at -20°C
for RNA extraction and quantification by qRT-PCR,
respectively, as described previously in this manuscript.
Flow cytometry on peripheral blood from patients
Flow cytometric (FC500, Beckman-Coulter, Hialeah, FL,
USA) expressions of cell surface markers was assessed
on EDTA-anticoagulated peripheral blood from patients.
Monoclonal antibodies and their respective isotype con-
trols were used according to manufacturer’s recommen-
dation: PE-labeled anti-HLA-DR (Becton Dickinson-
Pharmingen, San Jose, CA, USA), FITC-labeled anti-
CD14, ECD-labeled anti-CD4, PE-labeled anti-CD127,
PECy5-labeled anti-CD25 (Immunotech, Marseille,
France). Red blood cells were lysed using the automated
TQ-Prep lysing system (Beckman-Coulter, Miami, FL,
USA) in the case of Treg measurement or using FACS
lysing solution (Becton Dickinson-Pharmingen, San Jose,
CA, USA) for HLA-DR. Results are expressed as percen-
tages of CD4
+CD25
+CD127
- cells out of the total CD4
+
lymphocytes and as percentages of cells expressing
HLA-DR among total monocyte population. This work
belongs to a global study on ICU-induced immune dys-
functions. It has been approved by our Institutional
Review Board for ethics which waived the need for
informed consent because biomarkers expression was
measured on residual blood after completing routine fol-
low-up. This study is registered at French Ministry of
Research and Enseignement (#DC-2008-509). It is also
recorded at the Comission Nationale de l’Informatique
et des Libertés.
Statistical analysis
Results were expressed as mean ± standard deviation.
Statistical analysis was performed using the non-para-
metric Wilcoxon paired test for comparison between
culture conditions or using the Mann Whitney U-test
for comparison between septic patients and healthy
volunteers. A P value less than 0.05 was considered sig-
nificant with correction by the number of analyses
performed.
Results
Description of the model of endotoxin tolerance (ET)
Models of ET have been characterized by a reduction
of TNF-a production associated with an increase in
IL-10 secretion following a secondary stimulation with
LPS. These cytokines were therefore measured in
healthy volunteers’ PBMCs supernatant after two chal-
lenges with LPS (primed cells) in comparison with
cells that were only stimulated with LPS at 100 μg/ml
(unprimed cells - Figure 1a). As expected, in response
to a second LPS challenge, LPS-primed cells released
less TNF-a (58.5 ± 68.3 pg/mL) than unprimed cells
(1208 ± 594 pg/mL) and produced more IL-10 (63.2 ±
58.2 vs 8.4 ± 6.9 pg/mL in unprimed cells) (Figure 1b).
These results were confirmed at the mRNA level
(Figure 1c).
Table 1 Quantitative PCR performance, parameters and
primers
Gene symbol GenBank Primer sequences
a
IL-10 NM_000572.2 5’-AATAAGGTTTCTCAAGGGGCT-3’
5’-AGAACCAAGACCCAGACATCAA-3’
HLA-DRA NM_019111.4 5’-GCCAACCTGGAAATCATGACA-3’
5’-AGGGCTGTTCGTGAGCACA-3’
CIITA NM_000246.3 5’-GCTGGGATTCCTACACAATGC-3’
5’-CGGGTTCTGAGTAGAGCTCAATCT-3’
IRAK-M NM_007199.2 5’-TTTGAATGCAGCCAGTCTGA-3’
NM_001142523.1 5’-GCATTGCTTATGGAGCCAAT-3’
ABIN-3 NM_024873.4 5’-GAATTCCCAGATAAAAGCTTGT-3’
NM_001128843.1 5’-GACAGTCTGGTGGGTGCTC-3’
LY64 NM_005582.2 5’-GCATTGAGAAAGAAGCCAACAA-3’
5’-GAAAAGTGTCTTCATGTATCC-3’
a Top sequence is forward primer, bottom is reverse
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with an increase of IL-10 production in response to a
secondary endotoxin challenge in LPS-primed cells con-
firmed the development of an ET state in our model.
rIFN-g significantly improves TNF-a production in LPS-
deactivated PBMCs
Recombinant IFN-g has been proposed as a potential
immunostimulating therapy in septic shock or trauma
patients and preliminary clinical trials have provided
encouraging results [11-13]. Therefore, we tested the
effect of this drug in our model of ET.
In four preliminary experiments in healthy volunteers’
P B M C si n c u b a t e dw i t has i n g l ed o s eo fL P S( 2n g / m l ) ,
dose effect of rIFN-g on TNF-a and IL-10 gene expres-
sion levels was investigated. As shown in Figure 2, rIFN-
g dose-dependently increased TNF-a and decreased IL-
10 mRNA expression levels. On the basis of these
results and in agreement with previous reports
[11,20-22], cells were incubated with a drug dosage of
100 ng/ml in all further experiments.
We next investigated the effect of rIFN-g in 10 succes-
sive ET experiments in PBMCs from healthy volunteers.
As expected, we observed that incubation of primed cells
with rIFN-g before the second LPS challenge was asso-
ciated with a significant increase of TNF-a concentration
in the supernatant (Figure 3a). Interestingly, no effect
was observed on IL-10 concentration (Figure 3b). These
results were confirmed at the mRNA level as we observed
a significant up-regulation of TNF-a mRNA expression
following rIFN-g challenge compared with control values
(Figure 4a). As shown in Figure 4b, no variation in the
mRNA expression level of IL-10 was observed.
In addition, we monitored by qRT-PCR the expression
of five genes described in the literature to be involved in
the ET refractory state or sepsis-induced immunosup-
pression (HLA-DRA, CIITA, IRAK-M, ABIN-3,a n d
LY64) [7]. Our results showed that, in LPS-primed cells,
rIFN-g induced a significant up-regulation of HLA-DRA
and CIITA mRNA expressions (Figures 4c and 4d) asso-
ciated with a significant decrease in the expression level
of IRAK-M, ABIN-3 and LY64 (Figures 4e to 4g).
rIFN-g effect on septic shock patient’s whole blood
Finally, EDTA whole blood from eight septic shock
patients sampled within three days after the onset of
shock was incubated with rIFN-g. Clinical data are pre-
sented in Table 2. At the time of sampling, these
patients presented with a reduced percentage of HLA-
DR expressing monocytes (60%/39-67), Median/Q1-Q3),
a marked lymphopenia (0.6 × 10
3 lymphocytes/μl (0.6-
1)) and an increased percentage of circulating Treg cells
(11%/10-13). As expected, in response to LPS, patients
produced lower amount of TNF-a and significantly
more IL-10 protein than healthy controls (Figures 5a
and 5b). These results were confirmed at the mRNA
level (Figures 6a and 6b). Importantly, the addition of
rIFN-g significantly restored TNF-a and abrogated IL-
10 productions (Figures 5a and 5b). Those variations
were observed at the mRNA level in septic shock
patients (Figures 6a and 6b). Moreover and as observed
in our model of ET, rIFN-g induced a massive elevation
of HLA-DRA and CIITA mRNA expression levels but
had no effect on IRAK-M and LY64 (Figures 6c to 6f).
ABIN-3 mRNA expression level has a similar behavior
as IRAK-M. However, we could not conclude on ABIN-
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Figure 2 Recombinant IFN-g dose-response curves. mRNA expressions of (a) TNF-a and (b) IL-10 were quantified by quantitative RT-PCR in
peripheral blood mononuclear cells (PBMCs) from four healthy volunteers after lipopolysaccharide (LPS) incubation (2 ng/ml for 15 hours) and
treatment with or without (baseline) rIFN-g1b (at 1, 10 or 100 ng/ml) for 24 hours. Values are presented as means and standard deviations of
percentage above baseline. IFN, interferon.
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Page 5 of 113 since its mRNA values for control conditions (nonsti-
mulated cells) were below the lowest values of the stan-
dard curve (data not shown).
Discussion
It is now largely accepted that sepsis is characterized by
the development of profound immune dysfunctions
[1,2,23]. Such alterations could explain patients’ inability
to fight the primary bacterial infection and their
decreased resistance to secondary nosocomial infections.
As a consequence, sepsis-induced immune dysfunctions
may contribute largely to mortality. Among mechanisms
responsible for this immunosuppression, monocyte dys-
function, generically called ET, is believed to play a
pivotal role [2,6,7,24]. Clinically, the state of ET is asso-
ciated with functional and phenotypic alterations of cir-
culating monocytes. It has been demonstrated that
patients with the most severe monocyte dysfunctions
are those who have a greater risk of developing nosoco-
mial infections and a greater risk of dying [14,15,25].
Overall, these observations provide a rational for the
development of novel therapies aimed at boosting the
immune functions in septic patients.
ET can be partly mimicked ex vivo when cells from
healthy volunteers are activated by sequential LPS chal-
lenges [24,26,27]. Here, we took advantage of this model
to investigate the effects of a pro-inflammatory drug,
rIFN-g, which previously provided interesting prelimin-
ary results in small clinical studies [11-13]. We assessed
ex vivo drug effect through the monitoring of the
expression level of a panel of seven genes (i.e. TNF-a,
IL-10, HLA-DRA, CIITA, IRAK-M, ABIN-3 and LY64).
In the present experiments, we observed that rIFN-g
restored ex vivo the production of the pro-inflammatory
cytokine TNF-a, therefore reflecting monocyte function
improvement. We observed an increase in the expres-
sions of TNF-a, HLA-DRA and CIITA mRNA following
rIFN-g treatment in our model of ET. Importantly, a
similar increase in the expression of those genes was
also observed in the whole blood of septic shock
patients upon ex vivo rIFN-g challenge. Our data are in
agreement with previous literature [9,11]. The positive
effect of rIFN-g could be explained, in part, by the abil-
ity of IFN-g to enhance NF-B nuclear translocation in
response to LPS [20] and to induce recruitment of tran-
scription factors. Restoration of the accessibility to
endogenous promoters, in part by facilitating TLR-
induced chromatin remodeling [28], may also explain
the positive effect of rIFN-g on monocyte functionality.
Regarding the negative regulators of LPS signaling
pathway, we observed, in our model of ET, an increase
in the mRNA expression level of IRAK-M and ABIN-3.
It is important to note that these results are in agree-
ment with previous reports [29,30]. However, to our
knowledge, we show for the first time that rIFN-g
induced ex vivo a restoration of the TLR signaling path-
way, by decreasing both IRAK-M and ABIN-3 mRNA
expression levels. Such variation in gene expression
induced by rIFN-g might add to the understanding of
cell function recovery. In this model of ET, LY64 gene
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tolerance. mRNA expressions of (a) TNF-a, (b) IL-10, (c) HLA-DRA, (d) CIITA, (e) IRAK-M, (f) ABIN-3 and (g) LY64 were quantified by quantitative
RT-PCR in peripheral blood mononuclear cells (PBMCs) from 10 healthy volunteers after induction of endotoxin tolerance. Black columns
represent controls (cells without any lipopolysaccharide (LPS) stimulation), white columns indicate LPS-unprimed cells (only stimulated once with
100 ng/ml LPS) and dark grey columns show LPS-primed cells (two LPS stimulations: 2 ng/ml followed by 100 ng/ml) and light grey show LPS-
primed cells incubated with rIFN-g1b (100 ng/ml). Gene expression results are presented as a normalized ratio vs data obtained in unstimulated
cells (fold changes vs control). Data are presented as mean ± standard deviation. The Wilcoxon signed rank test was used to test for statistical
significance († P < 0.005 vs LPS-unprimed cells; ** P < 0.005 vs vehicle). IFN, interferon.
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Page 7 of 11expression, which is also a TLR4 signaling pathway reg-
ulator, was decreased as well in the presence of rIFN-g.
The exact role of LY64 on TLR signaling pathways is
not yet clearly established [25,31] and additional experi-
ments are needed to further address this point.
Regarding the effect of rIFN-g on IL-10 expression, we
observed discrepant results between the ET model on
healthy PBMCs and the ex vivo stimulation in whole
blood of septic patients. Indeed, at the protein and
mRNA levels, rIFN-g did not result in a decrease of IL-
10 in LPS-deactivated PBMCs. In a similar experimental
model, Randow et al.s h o w e da ni n c r e a s ei nt h eI L - 1 0
production in refractory cells exposed to IFN-g [22]. In
contrast we found that the IL-10 gene was down-regu-
lated by rIFN-g in whole blood cells from septic shock
patients. These results are in agreement with Nakos et
al. who observed that the administration of inhaled
IFN-g in immunoparalyzed patients resulted in an
increase of pro-inflammatory markers and a decrease of
anti-inflammatory molecules like IL-10 [13].
Importantly, this study highlights the potential of
using gene expression analysis to identify novel biomar-
kers that could contribute to a more personalized medi-
cine. It is now well established that biomarkers will be
useful (i) to identify patients eligible for immunomodu-
latory therapies, (ii) to monitor response to treatment,
and (iii) to evaluate benefit/risk ratio. So far, flow cyto-
metric measurement of HLA-DR expression on circulat-
ing monocytes has appeared as a reliable biomarker for
the prediction of death and nosocomial infections in
septic patients [14,15,32]. Small clinical trials have used
this parameter to stratify ICU patients before adminis-
tration of rIFN-g [11,13]. However, pre-analytical and
analytical issues inherent to HLA-DR measurement by
flow cytometry limit its use in large multicentered clini-
cal studies and on a routine basis [33]. Based on the
results of the current study and on previous investiga-
tions showing the correlation between mRNA and pro-
tein expression levels for this parameter [32,34], HLA-
DR and CIITA mRNA measurements appear as promis-
ing gene candidates for the monitoring of response to
immunomodulatory therapies. This is all the more
because the availability in routine labs of molecular biol-
ogy platforms will enable standardized and routine use
of such biomarkers.
In total, given that gene expression profiling is now
recognized to offer meaningful data, it provides a new
perspective in the prognosis and monitoring of septic
patients and offers the foundation for possible auto-
mated tests with standardized methodologies. As an
Table 2 Demographic and clinical data for septic shock
patients
Parameters Patients (n =8 )
Age at admission (years) 75 (64-79)
Gender (male) 6 (75%)
SOFA score 11 (11-12)
SAPS II score 55 (48-64)
% HLA-DR
+ monocytes 60 (39-67)
% of regulatory T cells (among CD4
+ lymphocytes) 11 (10-13)
Number of lymphocytes (10
3/μl) 0.6 (0.6-1)
Sampling time (Days after shock) 1 (1-1)
Mortality (survivors) 4 (50%)
Results are presented as median and interquartile range (Q1-Q3) for
continuous variables or as number of cases and percentages (%) for
categorical data.
SAPS II, Simplified Acute Physiology Score II measured on admission; SOFA
score, Sequential Organ Failure Assessment measured during the first 24
hours of ICU stay.
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Figure 5 TNF-a and IL-10 productions after incubation with recombinant IFN-g and LPS in whole blood from septic shock patients. (a)
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Page 8 of 11example, based on microarray data, Pachot et al.i d e n t i -
fied the loss of CX3CR1 as a new feature of sepsis-
induced immunosuppression [25,35]. Wolk et al.
observed that a reduction of CD86 mRNA expression
level coupled with a low HLA-DR level is associated
with an unfavorable prognosis in ICU patients with
post-inflammatory immunodeficiency [36]. Recently,
Hinrichs et al. followed the expression level of 23
mRNAs related to inflammation in patients after surgery
[37]. They showed that TNF, IL1-b,C D 3 Dand PRF1
gene expressions were significantly different in patients
who developed postoperative sepsis in comparison with
patients who recovered uneventfully. In addition, their
results demonstrate that the combination of TNF, IL1-b
and CD3D mRNA expression levels is able to predict
secondary infections with an extremely good area under
the curve of 0.92.
Our study has some limitations. First, as mentioned
previously, seminal studies of immunostimulatory ther-
apy in sepsis have shown that patients’stratification by
their relative immunoparalysis, as evidenced by low cir-
culating HLA-DR monocytes could improve treatment
efficacy [11,13]. As this preliminary study was designed
as a proof of concept to monitor response to ex vivo
rIFN-g through the expression level of genes, this para-
meter, although included in the analysis, was not a
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expressions of (a) TNF-a, (b) IL-10, (c) HLA-DRA, (d) CIITA, (e) IRAK-M and (f) LY64 were quantified by quantitative RT-PCR in EDTA whole blood
from eight septic shock patients sampled within three days after the onset of shock (black columns) and eight healthy volunteers (open
columns), stimulated or not (control) with lipopolysaccharide (LPS; 100 ng/ml) ± rIFN-g1b (100 ng/ml) for one night. Data are presented as mean
± standard deviation. Comparison between healthy volunteers and septic shock patients treated with LPS was performed using the Mann-
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Page 9 of 11criterion for patients’ inclusion. Nevertheless, at the time
of sampling, mHLA-DR expression in patients was
decreased in comparison with normal values (Table 2).
In further studies investigating this aspect, stratification
based on mHLA-DR expression should be performed
and it should be investigated whether ex vivo rIFN-g
effect is more important in patients with low mHLA-DR
expression. Second, the comparison between results in
whole blood and in the model of ET shows some discre-
pancies. Without mentioning the difference in cell sub-
populations, it is obvious that the mechanisms involved
in monocyte dysfunctions partly differ between the two
models. Indeed, ex vivo model of endotoxin tolerance
uses only LPS to induce monocyte alterations whereas,
in septic patients, many more parameters (IL-10, corti-
sol, treatments...) have been shown to impact monocyte
functionality. This could explain differences between
results obtained in ET model and in whole blood experi-
ments. With that said, overall our results remain consis-
tent between the two models.
Conclusions
As sepsis-acquired immunosuppression appears asso-
ciated with increased risk of death and of nosocomial
infection, immunostimulatory approaches able to restore
cell dysfunctions represent innovative and promising
therapeutic strategies. In this study, we propose to fol-
low the expression levels of a panel of genes to assess ex
vivo monocyte-stimulating drug efficacy. The value of
such biomarker panel deserves now to be evaluated in a
large cohort of patients.
Key messages
￿ Recombinant human IFN-g increases TNF-a, HLA-
DRA and CIITA mRNA expression levels in an ex
vivo model of ET and in cells from septic shock
patients.
￿ Recombinant human IFN-g decreases IRAK-M and
ABIN-3 mRNA expression levels in an ex vivo model
of ET.
￿ This ex vivo translational research study demon-
strates the potential of a mRNA-based approach to
successfully monitor drug efficacy.
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